Nanovaccine for eliciting 10E8-like bnAbs against HIV-1

用于引发针对 HIV-1 的 10E8 样 bnAb 的纳米疫苗

• 批准号: 10441663
• 负责人: CHOWDA REDDY
• 金额: $ 30万
• 依托单位: NEOVAXSYN, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10441663
• 关键词: Affinity; Antibody Response; Antigens; Contracts; HIV; HIV vaccine; HIV-1; Membrane; Messenger RNA; Nucleic Acids; Proteins; RNA; RNA amplification; base; monomer; nanoparticle; nanoparticle delivery; nanovaccine; neutralizing antibody; next generation; particle

Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to develop, evaluate, and optimize nanoparticle-based platforms to elicit broadly neutralizing antibodies against the membrane proximal external region (MPER) of the HIV-1 gp41 protein.

作为下一代HIV疫苗的HIV免疫原的基于颗粒的共递送：定制免疫原（如Envs、单体、天然和/或天然样三聚体、核酸/RNA如mRNA，自扩增RNA）与用于递送的纳米颗粒上的有效多价抗原展示相结合，可以提供一种策略，以促进强的和长时间的活的抗HIV中和抗体应答和直接的HIV中和抗体亲和力成熟。该合同的目的是开发，评估和优化基于纳米颗粒的平台，以引发针对HIV-1 gp 41蛋白的膜近端外部区域（MPER）的广泛中和抗体。